Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
References
- Tobaiqy, M.; Qashqary, M.; Al-Dahery, S.; Mujallad, A.; Hershan, A.A.; Kamal, M.A.; Helmi, N. Therapeutic management of patients with COVID-19: A systematic review. Infect. Prev. Pract. 2020, 2, 100061. [Google Scholar] [CrossRef]
- Daou, F.; Abou-Sleymane, G.; Badro, D.A.; Khanafer, N.; Tobaiqy, M.; Al Faraj, A. The history, efficacy, and safety of potential therapeutics: A narrative overview of the complex life of COVID-19. Int. J. Environ. Res. Public Health 2021, 18, 955. [Google Scholar] [CrossRef] [PubMed]
- Alhumaid, S.; Mutair, A.A.; Alawi, Z.A.; Alhmeed, N.; Zaidi, A.R.Z.; Tobaiqy, M. Efficacy and safety of lopinavir/ritonavir for treatment of COVID-19: A systematic review and meta-analysis. Trop. Med. Infect. Dis. 2020, 5, 180. [Google Scholar] [CrossRef] [PubMed]
- Palma, G.; Pasqua, T.; Silvestri, G.; Rocca, C.; Gualtieri, P.; Barbieri, A.; De Bartolo, A.; De Lorenzo, A.; Angelone, T.; Avolio, E.; et al. PI3Kδ inhibition as a potential therapeutic target in COVID-19. Front. Immunol. 2020, 11, 2094. [Google Scholar] [CrossRef] [PubMed]
- WHO Official Website. Draft Landscape of COVID-19 Candidate Vaccines. Available online: https://www.who.int/publications/m/item/draft-landscape-of-COVID-19-candidate-vaccines (accessed on 3 March 2021).
- Le Thanh, T.T.; Andreadakis, Z.; Kumar, A.; Román, R.G.; Tollefsen, S.; Saville, M.; Mayhew, S. The COVID-19 vaccine development landscape. Nat. Rev. Drug Discov. 2020, 19, 305–306. [Google Scholar] [CrossRef] [PubMed]
- AstraZeneca COVID-19 Vaccine’s Summary of Product Characteristics (for Healthcare Professionals). Available online: https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-astrazeneca-product-information-approved-chmp-29-january-2021-pending-endorsement_en.pdf (accessed on 16 March 2021).
- Chung, E.H. Vaccine allergies. Clin. Exp. Vaccine Res. 2014, 3, 50–57. [Google Scholar] [CrossRef] [PubMed]
- EMA Recommends COVID-19 Vaccine AstraZeneca for Authorisation in the EU. Available online: https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-astrazeneca-authorisation-eu (accessed on 3 March 2021).
- Reg 174 Information for UK Healthcare Professionals. Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/976815/Information_for_Healthcare_Professionals_on_COVID-19_Vaccine_AstraZeneca.pdf (accessed on 9 April 2021).
- Voysey, M.; Clemens, S.A.C.; Madhi, S.A.; Weckx, L.Y.; Folegatti, P.M.; Aley, P.K.; Angus, B.; Baillie, V.L.; Barnabas, S.L.; Bhorat, Q.E.; et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2020, 397, 99–111. [Google Scholar] [CrossRef]
- Wise, J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ 2021, 372, n699. [Google Scholar] [CrossRef] [PubMed]
- Boytchev, H. Covid-19: Germany struggles with slow uptake of Oxford AstraZeneca vaccine. BMJ 2021, 372, n619. [Google Scholar] [CrossRef] [PubMed]
- AstraZeneca. Update on the Safety of COVID-19 Vaccine AstraZeneca 14 March. Available online: https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-the-safety-of-covid-19-vaccine-astrazeneca.html (accessed on 14 March 2021).
- AstraZeneca. Update on the Safety of COVID-19 Vaccine AstraZeneca 18 March. Available online: https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-the-safety-of-covid-19-vaccine-astrazeneca.html (accessed on 18 March 2021).
- European Medicines Agency. EudraVigilance: European Database of Suspected Adverse Drug Reaction Reports. Available online: http://www.adrreports.eu/en/background.html (accessed on 15 March 2021).
- Postigo, R.; Brosch, S.; Slattery, J.; van Haren, A.; Dogné, J.M.; Kurz, X.; Candore, G.; Domergue, F.; Arlett, P. EudraVigilance medicines safety database: Publicly accessible data for research and public health protection. Drug Saf. 2018, 41, 665–675. [Google Scholar] [CrossRef] [PubMed]
- European Medicines Agency. Access to EudraVigilance Data. Available online: https://www.ema.europa.eu/en/documents/other/european-medicines-agency-policy-access-eudravigilance-data-medicinal-products-human-use-revision-4_en.pdf (accessed on 12 March 2021).
- Mahase, E. Covid-19: WHO says rollout of AstraZeneca vaccine should continue, as Europe divides over safety. BMJ 2021, 372, n728. [Google Scholar] [CrossRef] [PubMed]
- Schafer, A.I.; Levine, M.N.; Konkle, B.A.; Kearon, C. Thrombotic disorders: Diagnosis and treatment. Hematol. Am. Soc. Hematol. Educ. Program. 2003, 520–539. [Google Scholar] [CrossRef] [PubMed]
- Tapson, V.F. The role of smoking in coagulation and thromboembolism in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2005, 2, 71–77. [Google Scholar] [CrossRef] [PubMed]
- Slišković, A.M.; Puljević, M.; Šutalo, A.; Bosnić, A.; Banfić, L.; Vrkić Kirhmajer, M. Prevalence of non-COVID-19 venous thromboembolism during SARS-CoV-2 outbreak: Our experience. Cardiol. Croatica. 2021, 16, 71. [Google Scholar] [CrossRef]
- Sardella, M.; Lungu, C. Evaluation of quantitative signal detection in EudraVigilance for orphan drugs: Possible risk of false negatives. Ther. Adv. Drug Saf. 2019, 10, 2042098619882819. [Google Scholar] [CrossRef] [PubMed]
- Stewart, J.A.; Hamilton, P.J.; Murdoch, A.P. Thromboembolic disease associated with ovarian stimulation and assisted conception techniques. Hum. Reprod. 1997, 12, 2167–2173. [Google Scholar] [CrossRef] [PubMed]
- Baumann, P.; Diedrich, K. Thromboembolic complications associated with reproductive endocrinologic procedures. Hematol. Oncol. Clin. N. Am. 2000, 14, 431–443. [Google Scholar] [CrossRef]
- O’Connell, K.A.; Wood, J.J.; Wise, R.P.; Lozier, J.N.; Braun, M.M. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006, 295, 293–298. [Google Scholar] [CrossRef] [PubMed]
- Barletta, J.F.; Cooper, B.; Ohlinger, M.J. Adverse drug events associated with disorders of coagulation. Crit Care Med. 2010, 38 (Suppl. 6), S198–S218. [Google Scholar] [CrossRef] [PubMed]
- Stegeman, B.H.; De Bastos, M.; Rosendaal, F.R.; Vlieg, A.V.H.; Helmerhorst, F.M.; Stijnen, T.; Dekkers, O.M. Different combined oral contraceptives and the risk of venous thrombosis: Systematic review and network meta-analysis. BMJ 2013, 347, f5298. [Google Scholar] [CrossRef] [PubMed]
- Joint Council on Vaccination and Immunisation. Statement of Immunisation Prioritisation. Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/950113/jcvi-advice-on-priority-groups-for-covid-19-vaccination-30-dec-2020-revised.pdf (accessed on 12 March 2021).
- European Medicines Agency. Emergency Meeting of Pharmacovigilance Risk Assessment Committee (PRAC). Available online: https://www.ema.europa.eu/en/events/extraordinary-meeting-pharmacovigilance-risk-assessment-committee-prac-18-march-2021 (accessed on 18 March 2021).
- UK Government. MHRA Issues New Advice, Concluding a Possible Link between COVID-19 Vaccine AstraZeneca and Extremely Rare, Unlikely to Occur Blood Clots. Available online: https://www.gov.uk/government/news/mhra-issues-new-advice-concluding-a-possible-link-between-covid-19-vaccine-astrazeneca-and-extremely-rare-unlikely-to-occur-blood-clots (accessed on 7 April 2021).
Variable | Level | n (%) |
---|---|---|
Gender | Male | 9 (32.1) |
Female | 19 (67.9) | |
Reporter profession | Healthcare Professional | 19 (67.9) |
Non-Healthcare Professional | 9 (32.1) | |
Geographical area | EU | 13 (46.4) |
Non-EU | 15 (53.6) | |
Age group of patients | 18–64 Years | 3 (10.7) |
65–85 Years | 9 (32.1) | |
More than 85 Years | 16 (57.1) |
Receipt Date * (DD/MM/YYYY) | Primary Source Qualification | Primary Source Country | Age Group | Sex |
---|---|---|---|---|
17/02/2021 | Healthcare Professional | Non-EU | 18–64 Years | Male |
18/02/2021 | Healthcare Professional | Non-EU | More than 85 Years | Female |
23/02/2021 | Healthcare Professional | Non-EU | 65–85 Years | Male |
02/03/2021 | Healthcare Professional | Non-EU | 65–85 Years | Female |
03/03/2021 | Healthcare Professional | Non-EU | 18–64 Years | Female |
06/03/2021 | Non-Healthcare Professional | Non-EU | 65–85 Years | Female |
06/03/2021 | Healthcare Professional | Non-EU | More than 85 Years | Female |
06/03/2021 | Non-Healthcare Professional | Non-EU | 65–85 Years | Female |
06/03/2021 | Healthcare Professional | Non-EU | More than 85 Years | Female |
06/03/2021 | Non-Healthcare Professional | Non-EU | 65–85 Years | Male |
06/03/2021 | Healthcare Professional | Non-EU | 65–85 Years | Male |
07/03/2021 | Non-Healthcare Professional | Non-EU | 18–64 Years | Female |
07/03/2021 | Healthcare Professional | Non-EU | 18–64 Years | Female |
07/03/2021 | Healthcare Professional | Non-EU | 65–85 Years | Female |
07/03/2021 | Healthcare Professional | Non-EU | 65–85 Years | Male |
08/03/2021 | Healthcare Professional | EU | 18–64 Years | Female |
08/03/2021 | Healthcare Professional | EU | 65–85 Years | Female |
09/03/2021 | Healthcare Professional | EU | 18–64 Years | Female |
09/03/2021 | Healthcare Professional | EU | 18–64 Years | Male |
10/03/2021 | Healthcare Professional | EU | 18–64 Years | Female |
10/03/2021 | Non-Healthcare Professional | EU | 18–64 Years | Male |
10/03/2021 | Non-Healthcare Professional | EU | 18–64 Years | Female |
10/03/2021 | Healthcare Professional | EU | 18–64 Years | Female |
11/03/2021 | Healthcare Professional | EU | 18–64 Years | Male |
11/03/2021 | Non-Healthcare Professional | EU | 18–64 Years | Female |
11/03/2021 | Non-Healthcare Professional | EU | 18–64 Years | Female |
12/03/2021 | Healthcare Professional | EU | 18–64 Years | Female |
12/03/2021 | Non-Healthcare Professional | EU | 18–64 Years | Male |
Age Group | Reaction Type | Concomitant Conditions | Outcome |
---|---|---|---|
18–64 Years (n = 12) | Cerebral venous sinus thrombosis, pulmonary embolism | Haemorrhage intracranial, immune thrombocytopenia, peripheral artery thrombosis | Not Resolved |
Carotid artery thrombosis, peripheral artery thrombosis | Thrombocytopenia, cerebrovascular accident | Not Resolved | |
Thrombosis | Chest discomfort, chest pain | Resolved | |
Pelvic vein thrombosis, pulmonary embolism | Thrombocytopenia, blood fibrinogen decreased, dyspnea, fatigue | Resolving | |
Thrombosis | Uterine haemorrhage | Resolving | |
Deep vein thrombosis | N/A | Unknown | |
Deep vein thrombosis | Purpura, pyrexia (recovered) | Resolving | |
Deep vein thrombosis, pulmonary embolism | Chest pain, fatigue, pain in extremities | Resolving | |
Deep vein thrombosis, pulmonary embolism | N/A | Fatal | |
Deep vein thrombosis | N/A | Resolved with Sequelae | |
Deep vein thrombosis | N/A | Resolved | |
Pelvic venous thrombosis | N/A | Not Resolved | |
65–85 Years (n = 4) | Deep vein thrombosis | Malaise | Resolving |
Thrombosis | Pyrexia | Resolving | |
Deep vein thrombosis | Pyrexia | Unknown | |
Deep vein thrombosis | Guillain–Barre syndrome | Unknown | |
More than 85 Years (n = 3) | Deep vein thrombosis | N/A | Resolving |
Deep vein thrombosis, pulmonary embolism | N/A | Unknown | |
Deep vein thrombosis, pulmonary embolism | Lethargy | Fatal |
Age Group | Reaction | Concomitant Conditions | Outcome |
---|---|---|---|
18–64 Years | Thrombophlebitis | Pain | Resolving |
Thrombosis | Flu-like illness | Resolving | |
Thrombosis | Arthralgia, thrombocytopenia, Pain in extremities, pyrexia | Fatal | |
Deep vein thrombosis | N/A | Not Resolved | |
Deep vein thrombosis | N/A | Resolving | |
65–85 Years | Thrombophlebitis | N/A | Not Resolved |
Deep vein thrombosis | N/A | Resolving | |
Thrombosis | N/A | Not Resolved | |
Deep vein thrombosis | Cellulitis, lymphadenitis | Unknown |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tobaiqy, M.; Elkout, H.; MacLure, K. Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database. Vaccines 2021, 9, 393. https://doi.org/10.3390/vaccines9040393
Tobaiqy M, Elkout H, MacLure K. Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database. Vaccines. 2021; 9(4):393. https://doi.org/10.3390/vaccines9040393
Chicago/Turabian StyleTobaiqy, Mansour, Hajer Elkout, and Katie MacLure. 2021. "Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database" Vaccines 9, no. 4: 393. https://doi.org/10.3390/vaccines9040393
APA StyleTobaiqy, M., Elkout, H., & MacLure, K. (2021). Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database. Vaccines, 9(4), 393. https://doi.org/10.3390/vaccines9040393